Another 36 executives left, the second half of the pharmaceutical companies "departure tide" is still.

Pharmaceutical Network Industry Dynamics: In the first half of this year, more than 100 listed pharmaceutical executives have changed positions.
But according to incomplete statistics, since July 2020, only the biopharmaceutical sector listed companies have 30 enterprises, 36 listed company executives resigned, including 10 positions as deputy general manager, involving Jiangsu Hengrui, Gan Li Pharmaceuticals, Fosun Pharma, Junshi Bio and many other well-known pharmaceutical companies.
according to the announcement of listed companies, the reasons for executive resignation are mostly personal reasons, job changes, age reasons and so on.
, personal reasons still dominate.
E.e., on August 10, Fish Leap Medical announced that on August 10, 2020, the Board of Directors of the Company received a written resignation report from Zhao Chunsheng, Vice President (Deputy General Manager) of the Company, who requested his resignation as Vice President (Deputy General Manager) of the Company for personal reasons.
Zhao Chunsheng resigns, he will no longer hold any positions in the company.
July 29, Fangsheng Pharmaceuticals also announced that on July 28, Vice General Manager Zhou Weien applied for resignation for personal reasons from the Company's Deputy General Manager and all positions he held in subsidiaries of the Company, and will no longer hold any positions in the Company.
addition, looking at the changes in people so far this year, it is clear that some enterprises have more frequent changes in personnel, and even the phenomenon of collective resignation of senior executives.
For example, in the first half of the year, Fosun Pharma, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals and Lisheng Pharmaceuticals all had more than 4 employees in the first half of this year, while Fosun Pharma had executive departures in the second half of the year.
the same time, the second half of Gan Li Pharmaceutical also left three people, respectively, general manager, deputy general manager, financial director, but it is worth noting that the above three resignations will still be in Gan Li Pharmaceuticals to engage in related work.
fact, the new chairman of People's Fu Pharmaceuticals has told the media that the personnel changes are mainly in line with the company's strategic adjustment.
, it also mentioned that "nuclear focus" will become the main development strategy of the future of human medicine.
, the industry agrees that the personnel adjustment of pharmaceutical enterprises is the inevitable result of the drastic changes in the pharmaceutical industry pattern and the re-shaping of the pharmaceutical market pattern.
especially in the case of overlay of the epidemic, policy-intensive introduction, market changes, pharmaceutical companies inevitably need to change personnel to adapt to drastic changes.
, in the context of long-term industrial upgrading and increased concentration, pharmaceutical enterprises, pharmaceutical practitioners will face an inevitable journey of survival of the fittest.
in general, in the current situation, pharmaceutical enterprises to consider more things than before, research and development, marketing, product structure, policy should be carefully considered.
especially the policy, the new policy situation, enterprises are not only facing public hospitals, but also private hospitals, pharmacies, and even online medical treatment, which need to be based on different policies to develop different development ideas.
Whether foreign or local pharmaceutical enterprises need to make adjustments in business structure, business thinking, management thinking, product structure and research and development layout as soon as possible, in order to adapt to the Chinese pharmaceutical industry, which is undergoing great changes under the reform of medicine.
.